ArticleNPJ precision oncology2022

Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies.

Michael E Lidsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.